N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B. Its vaccines include Nuvac and Nuvec. The Company is improving Sildenafil for erectile dysfunction. Sartans is a family of drugs known as Angiotensin II antagonists, including Losartan and Valsartan, commonly used for the treatment of hypertension. Aprepitant is an anti-emetic drug used in oncology. It is reformulating the existing Hepatitis B surface antigen vaccine (HBsAg), a sub unit vaccine. Nuvac is a nano-carrier delivery system for vaccines. Nuvec is an engineered silica nanoparticle, which has been designed for the intracellular delivery of large nucleic acids such as plasmid deoxyribonucleic acid and messenger ribonucleic acid
PIWORLD provides investors with the latest news and insight to listed companies and their management teams through either live or recorded results presentations, corporate overviews, management interviews and Capital Market Days. Together with interviews from leading fund managers, market specialists and esteemed private investors, we aim to keep the private investor community up to date and informed.
PIWORLD delivers high quality audio and video content to present anything from full-year and interim results to Capital Markets Days and corporate overviews. We bridge the gap between listed companies and the private investor community, who drive the share price and provide liquidity, providing a time and cost effective medium to reach this diverse and important audience.
